The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
出版年份 2016 全文链接
标题
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
作者
关键词
Atherosclerosis, Insulin resistance, Sodium glucose cotransporter, Type 2 diabetes
出版物
DIABETOLOGIA
Volume 60, Issue 2, Pages 364-376
出版商
Springer Nature
发表日期
2016-11-19
DOI
10.1007/s00125-016-4158-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Pathophysiology of lipid droplet proteins in liver diseases
- (2016) Rotonya M. Carr et al. EXPERIMENTAL CELL RESEARCH
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis
- (2015) Soo Lim et al. ATHEROSCLEROSIS
- Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
- (2015) Soo Lim et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice
- (2015) Kenichi Nakajima et al. International Journal of Endocrinology
- Adipokines, diabetes and atherosclerosis: an inflammatory association
- (2015) Leandro C. Freitas Lima et al. Frontiers in Physiology
- Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis
- (2015) Sathish Babu Vasamsetti et al. DIABETES
- Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
- (2015) Michishige Terasaki et al. PLoS One
- Modulation of adiponectin as a potential therapeutic strategy
- (2014) Soo Lim et al. ATHEROSCLEROSIS
- C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells
- (2014) Fang Bian et al. BRITISH JOURNAL OF PHARMACOLOGY
- Impact of MCP -1 in Atherosclerosis
- (2014) Juntang Lin et al. CURRENT PHARMACEUTICAL DESIGN
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular and hemodynamic effects of glucagon-like peptide-1
- (2014) Adam G. Goodwill et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Identification of Cardiometabolic Risk: Visceral Adiposity Index Versus Triglyceride/HDL Cholesterol Ratio
- (2013) Martin R. Salazar et al. AMERICAN JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Hepatictrans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly
- (2013) Deike Hesse et al. JOURNAL OF LIPID RESEARCH
- Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
- (2012) L. Chen et al. CURRENT MOLECULAR MEDICINE
- Stress Augments Insulin Resistance and Prothrombotic State: Role of Visceral Adipose-Derived Monocyte Chemoattractant Protein-1
- (2012) Y. Uchida et al. DIABETES
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
- (2011) K Yamamoto et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats
- (2011) Soo Lim et al. CARDIOVASCULAR RESEARCH
- Reduced Adipose Tissue Inflammation Represents an Intermediate Cardiometabolic Phenotype in Obesity
- (2011) Melissa G. Farb et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Modulation of lipid droplet size and lipid droplet proteins by trans-10,cis-12 conjugated linoleic acid parallels improvements in hepatic steatosis in obese, insulin-resistant rats
- (2010) Danielle M. Stringer et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects
- (2008) Caroline M. Apovian et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
- (2008) Katerina Papathanassiou et al. ATHEROSCLEROSIS
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation